Exploratory RNA sequencing (RNAseq) analyses
tumor
TUMOR
RNAseq was performed on baseline tumor biopsies from 53 patients, including 35 patients in Arm A and 18 patients in Arm B. Among the 35 patients in Arm A, 34 were evaluable for FDG-PET response (19 responders and 15 non-responders). Among them, 26 patients (15 responders and 11 non-responders) had both pre- and post-afatinib tumor samples with available gene expression data analysis (Supplementary Fig. 